Cyrus Harmon sold $205k of OLMA
director at Olema Pharmaceuticals, Inc.. 25,000 shares at an average of $8.19, traded Sep 16, 2025, filed Sep 18, 2025.
Score components
- +15RoleDirector
- +12Trade size$205k at market
- 0Share of holdings soldSold 3.3% of holdings
- 0ClusterNo other insider selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +10.0%, 3m +262.0%, 6m +75.8%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001831410-25-000004, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Sep 16, 2025 | SOpen-market sale Common Stock | -10,000 | $8.04 | $80k | 754,140 | Sep 18, 2025 |
| Sep 18, 2025 | SOpen-market sale Common Stock | -10,000 | $8.33 | $83k | 744,140 | Sep 18, 2025 |
| Sep 16, 2025 | SOpen-market sale Common Stockindirect: See Footnote | -1,914 | $8.08 | $15k | 120,114 | Sep 18, 2025 |
| Sep 18, 2025 | SOpen-market sale Common Stockindirect: See Footnote | -3,086 | $8.32 | $26k | 117,028 | Sep 18, 2025 |
Related signals
Other insiders at Olema Pharmaceuticals, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 29Weak | OLMAsell Olema Pharmaceuticals, Inc. | Cyrus Harmon director | $291k 25,000 shares | -3% | |
| 44Moderate | OLMAsell Olema Pharmaceuticals, Inc. | Shawnte Mitchell CHIEF LEGAL OFFICER | $952k 40,000 shares | -267% | |
| 43Moderate | Olema Pharmaceuticals, Inc. | Cyrus Harmon director | $269k 10,000 shares | -1% | |
| 40Moderate | Olema Pharmaceuticals, Inc. | Cyrus Harmon director | $102k 3,489 shares | -0% | |
| 65Notable | Olema Pharmaceuticals, Inc. | Shane William Charles Kovacs CH. OPERATING & FINANCIAL OFF. | $3.0M 103,822 shares | -43% | |
| 60Notable | Olema Pharmaceuticals, Inc. | David C. Myles CH. DISCOV. & NON-CLIN DEV OFF | $3.1M 110,000 shares | -71% | |
| 39Weak | Olema Pharmaceuticals, Inc. | Cyrus Harmon director | $82k 2,881 shares | -0% | |
| 60Notable | Olema Pharmaceuticals, Inc. | Ian T Clark director | $7.9M 264,800 shares | -100% | |
| 55Moderate | Olema Pharmaceuticals, Inc. | David C. Myles CH. DISCOV. & NON-CLIN DEV OFF | $1.6M 51,000 shares | -8% | |
| 60Notable | Olema Pharmaceuticals, Inc. | Naseem Zojwalla Chief Medical Officer | $7.5M 269,509 shares | -155% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.